Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4459 Sequential alkylating therapy and pembrolizumab induce near-complete response in high tumour mutational burden pancreatic neuroendocrine tumour: A case report

Introduction: Traditional treatment for neuroendocrine tumours (NETs), including surgery, somatostatin therapy, and targeted therapy, often fails in advanced disease. Alkylating therapy can increase tumour mutational burden (TMB), and the recent KEYNOTE-158 study approved pembrolizumab for advanced solid tumours with a high TMB.

Conference:

Presenting Author:

Authors: Paranjpe I, Hornbacker K, Vadde S, Fisher G, Shaheen S,

Keywords: pancreatic neuroendocrine tumour, immunotherapy, pembrolizumab, tumour mutational burden, TMB,